Ontology highlight
ABSTRACT:
SUBMITTER: Liu Q
PROVIDER: S-EPMC5817859 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
Liu Qian Q Yu Shengnan S Zhao Weiheng W Qin Shuang S Chu Qian Q Wu Kongming K
Molecular cancer 20180219 1
Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment. Two central mechanisms are involved in the resistant process: EGFR secondary mutations and bypass signaling activations. In an EGFR-dependent manner, acquired mutations, such as T790 M, interfere ...[more]